Biotechnology and Pharmaceuticals

April 24, 2014

Topics covered: Orphan Drugs, Orphan Drug and Biologics Manufacturing, Oncology Drug Development, Health Care, Genetic and Cell Therapies, FDA Approval Process, Biotechnology and Pharmaceuticals, Biotechnology and Pharmaceutical Companies Valuation

Companies covered: MannKind Corporation (NASDAQ:MNKD), Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA), Oragenics, Inc. (AMEX:OGEN), Cempra, Inc. (NASDAQ:CEMP), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Theravance, Inc. (NASDAQ:THRX), Pharmacyclics, Inc. (NASDAQ:PCYC), Merck & Company, Inc. (NYSE:MRK), InterMune Inc., Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), Idenix Pharmaceuticals Inc., Gilead Sciences, Inc. (NASDAQ:GILD), Curis, Inc. (NASDAQ:CRIS), Cubist Pharmaceuticals Inc., Bristol-Myers Squibb Company (NYSE:BMY), Celgene Corporation (NASDAQ:CELG), NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), Celladon Corporation (NASDAQ:CLDN), bluebird bio, Inc. (NASDAQ:BLUE), Amgen Inc. (NASDAQ:AMGN), Novartis AG (NYSE:NVS), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Dendreon Corp., Novo Nordisk A/S (NYSE:NVO), GlaxoSmithKline PLC (NYSE:GSK)

Buy ($175)

Pin It on Pinterest

Share This